Keven Michon

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN @Ocugen
@drsmusunuri please look into this, it appears to be a genuinely solid, bona fide analysis. Time and again, retail investors are proving they can outperform many so-called financial analysts. The market will eventually wake up to these realistic revenue projections.

[TheUrbanFarmer @NattaCop]

$OCGN OCU400 broad RP analysis, realistic revenue projections, and a bonus market cap/share price timeline. Most won’t realize how conservative this framework actually is. 🍻

[AmlDean @amldean19]

#OCUGEN Here's the Noble vid from yesterday with @drsmusunuri. Q3 looks to be a busy quarter with OCU410ST interm analysis to see if any changes need to be made to the trial, start of the rolling BLA for OCU400 and the start of the OCU410 "Global trial"💪
https://t.co/XqGcuV3gl5

[Ocugen @Ocugen]

What is #RetinitisPigmentosa (RP)?

RP is a rare inherited eye disease that can lead to vision loss over time. More than 150 genetic mutations can cause RP. #OCU400 is designed to address over 98% RP-associated gene mutations with a single dose. Share to raise awareness. $OCGN

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

@Ocugen @drsmusunuri 👏👏👏

https://t.co/Ip2AIVGfzF

[Ivan @IvandeaGreat]

@amldean19

$OCGN

[AmlDean @amldean19]

$ocgn #Ocugen Great presentation by Abhi. https://t.co/aBB3h7lTWM

[AFT Thoughts @AFTFuture2099]

🚨 $OCGN Elliott Wave Setup Just Got Interesting 🚨

The weekly chart is painting what could be a textbook Elliott Wave structure. 👀

✅ Wave 1 and 2 appear complete
✅ Wave 3 projects toward the $6-$9 zone
✅ Wave 4 consolidation expected
✅ Wave 5 could target $35-$50+ if momentum and fundamentals align

Meanwhile, Ocugen is advancing:

🧬 OCU400 (Retinitis Pigmentosa)
🧬 Stargardt Disease Program
🧬 Geographic Atrophy Program

If clinical milestones continue hitting and Wall Street starts pricing in commercial potential, this chart could look very different over the next few years.

Current price: ~$1.38

Potential Wave 3 target: $6-$9 📈
Potential full cycle target: $35-$50+ 🚀

The risk/reward here is why biotech attracts life-changing gains.

Not financial advice. Just sharing what the chart is showing.

#OCGN #Ocugen #Biotech #Stocks #Investing #ElliottWave #NASDAQ #RetinitisPigmentosa #OCU400 #Bullish 🚀🔥📊💎🙌

[AFT Thoughts @AFTFuture2099]

🚨 $OCGN JUST GOT REAL 🚨

Ocugen plans to start a rolling BLA submission for OCU400 in Q3 2026 — a potential game changer for Retinitis Pigmentosa. 👁️

✅ Phase 3 underway
✅ FDA filing targeted
✅ Topline data expected Q1 2027
✅ Potential approval in 2027

Unlike Luxturna, OCU400 is designed to be GENE-AGNOSTIC, targeting a much larger RP population.

At a ~$1 share price, Wall Street is sleeping on what could become one of the biggest blindness-treatment stories in biotech.

$OCGN #Biotech #RetinitisPigmentosa #GeneTherapy

[AFT Thoughts @AFTFuture2099]

🚨 Another #OCU400 Life Transformed! #Ocugen 🚨

JP just shared his personal journey with the OCU400 gene therapy, and the real-world improvements are absolutely incredible. Here is exactly what he experienced just weeks after his treatment:

💡 Low-Light Vision: Gone are the days of complete darkness. He went from seeing a "black hole" in shadows to seeing shades and details, allowing him to easily navigate stairs at night and spot glowing light switches in the dark. [25:58]

🎮 Motion Tracking: His peripheral vision has improved so much that objects now move smoothly instead of jumping around like a "5 FPS" video game. He’s even back to tracking players in fast-paced FPS games! [28:18]

📖 Reading Text: No more reading letter-by-letter as if looking "through a straw." He can now perceive entire words at once, drastically reducing the effort it takes to read. [29:53]

😭 Seeing Family Faces: The most emotional milestone: Finally seeing the whites of his daughter's eyes, her genuine smile, and reading her real facial expressions without having to guess. [35:47]

🚶‍♂️ Confident Mobility: He now walks side-by-side with his wife at the grocery store instead of having to follow her feet, moving with a massive boost in newfound confidence. [39:47]

This isn't just medical progress; it's the restoration of human connection and independence. 🧬👇
https://t.co/sCrjqCjQoQ
#Ocugen #OCGN #GeneTherapy #RetinitisPigmentosa #Biotech #VisionLoss

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇
#Russell3000 and #Russell2000

Hope you guys are aware of that!!!

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇
Congratulations @Ocugen!!!

[Ocugen @Ocugen]

What is #Stargardtdisease?

A rare inherited retinal disease that can cause central vision loss, often beginning early in life. Ocugen’s investigational #genetherapy candidate, #OCU410ST, is designed to target disease pathways. #Biotech $OCGN

[BRexNew @BRexNew]

@NeenaHaider Developed the science to provide curative treatments for #RetinitisPigmentosa #StargardtDisease #GeographicAtrophy

AAV tech known for effective delivery of gene molecules to treat #Blindness

Yet we wait @houmanhemmati @SecKennedy
#OCU400 #OCU410 #OCU410ST $OCGN

[TheUrbanFarmer @NattaCop]

One might first see all this pressure to force Marty Makary out of power and think, why would BP want Marty out if he’s the one making it easier for drugs to get approved?

Then you start realizing something deeper. That all these hoops, hurdles, delays, and red tape that everyone complains about are the same barriers that make it nearly impossible for smaller companies to navigate alone.

You start to wonder if these absurdities are really just overlooked flaws, or if they purposely became part of the design.

Then you start noticing that Big Pharma is thriving in a broken system where small companies take all the scientific risk for innovation, spending years bleeding through cash and fighting through constantly changing regulatory uncertainty, only to end up getting forced into partnerships and undervalued buyouts once the data finally proves value.

Then a question dawns on you, why would BP take all the early R&D risks themselves when the system allows them to wait, watch and then buy innovations at a great discount off the companies who were courageous enough to attempt to survive their gauntlet?

Marty’s FDA changes to the system is a massive direct threat to the most powerful companies in the world. The fact that BP hasn’t already kicked Marty out of power is impressive imo.

[AWAREOFSILENCE @AWAREOFSILENCE]

#OCUGEN OFFERING CLOSED #LETSGOO https://t.co/fieGaaPtLP

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN #OCU500

Interesting details....

[Hamiltoeser @Mr_Yambone]

$OCGN Should hear some news from WashU or NIAID soon for OCU500. It is now "Recuriting." Any day now.

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN @Ocugen

@drsmusunuri Thank you Sir!
Amazing solution to the game of chess 👏

#Oppenheimer with a price target of $10,
they just put their money where the mouth is ...

[Shankar Musunuri @drsmusunuri]

Encouraging to see continued progress across our pipeline and operations this quarter. With key milestones achieved and a strong balance sheet, we are well positioned as we advance toward the next phase of development and potential filings.

#GeneTherapy #Biotech